WO2000027352A1 - Topical compositions containing whey proteins - Google Patents
Topical compositions containing whey proteins Download PDFInfo
- Publication number
- WO2000027352A1 WO2000027352A1 PCT/US1999/026650 US9926650W WO0027352A1 WO 2000027352 A1 WO2000027352 A1 WO 2000027352A1 US 9926650 W US9926650 W US 9926650W WO 0027352 A1 WO0027352 A1 WO 0027352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- amount
- collagen
- skin
- whey protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the invention relates to topical compositions containing whey protein which significantly increase the synthesis of collagen in skin More specifically, the invention relates to topical compositions containing vitamin C. vitamin E and vitamin A in combination with whey protein which have collagen synthesis enhancing properties
- Collagen is a fibrous protein that is composed of a triple chain helix structure having a sequence of repeating ammo acids, glycine, and X and Y.
- X and Y being any ammo acid, but are usually prohne and hydro xyprolme
- the X and Y ammo acids, particularly proline. in addition to the presence of lmino acid residues, stabilize the helical structure of collagen
- Collagen constitutes one quarter of the total amount of protein in the human body It is the major fibrous element of skin, bone tendons, cartilage, ligaments and blood vessels Collagen represents about 70% of skin in terms of its dry weight and helps form the structural network of skin The presence of collagen provides strength and resiliency in skin While there are various types of collagen throughout the body, the collagen in skin is predominantly Type I and Type III, where 80% to 90% is Type I and the remaining 10% to 15% is Type III Other types of collagen in skin, for example. Type IV, V. and I t ⁇ mer are present in considerably smaller amounts
- Collagen is synthesized by fibroblasts It is believed that as skin ages, the dermis and the epidermis thin because fibroblasts lose their ability to react to growth factors for the proliferation and synthesis of collagen It has also long been recognized that there is a cause-and-effect relationship between prolonged and/or repeated exposure to UV light and the premature aging of skin Excessive exposure to the sun contributes substantially to premature reduction in the quality and quantity of collagen in skin These changes manifest themselves externally by ty pical signs of aging, such as deep lines and wrinkles, loss of elasticity, skin dryness and unevenness.
- topical compositions of the present invention provide a synergistic combination that unexpectedly enhances the stimulation of collagen synthesis.
- a boost in the production of collagen in the skin is important and is the object of the present invention.
- the present invention relates to cosmetic or pharmaceutical compositions containing whey protein for topical application to the skin and methods of enhancing collagen synthesis in the skin.
- the components of the composition comprise collagen enhancing effective amounts of (a) a retinoid (hereinafter referred to as vitamin A) and derivatives thereof, (b) an ascorbic acid (hereinafter referred to as vitamin C) and derivatives thereof, (c ) vitamin E and derivatives thereof, and (d) a hey protein.
- the vitamins E and C components are present in the composition in specific ranges and the vitamin C component is present in an amount less than the vitamin E component to boost collagen synthesis. Therefore, these compositions are useful in the treatment and prevention of the effects of aging and photoaging, i.e.. the damage to the skin which occurs as a result of a decrease in collagen synthesis in skin.
- Figure 1 illustrates the percent increase of collagen production (over media control) in response to the presence of 1 ) whey protein ("W P"); 2) vitamin C at a low level of 50 ⁇ g/ml ("V-C 50"); 3) vitamin C at a high level of 100 ⁇ g/ml (" * V-C 100"); 4) whey protein with vitamin C at a low level of 50 ⁇ g ml (" W P/V-C 50"); 5) whey protein with vitamin C at a high level of 100 ⁇ g/ml ('"W P -C 100 '” ); 6) hey protein, vitamin A, and vitamin C at a low level of 50 ⁇ g/ml (“W P/V-C 50/V-A”), 7) whey protein, vitamin A, and vitamin C at a high level of 100 ⁇ g/ml C'W P/V-C 100/V-A”), 8) whey protein, vitamin A, vitamin C at a low level of 50 ⁇ g/ml
- a first component of the present invention is the whey protein component.
- Whey protein or serum lactis, exists in the supernatant of milk and is the portion of milk left over after butterfat, casein and albumin are removed. Since whey proteins are globular, they are, therefore, water soluble and subject to denaturation which increases their ability to hold water.
- the primary fractions of whey protein are ⁇ -lactoglobulins, ⁇ -lactalbumins, bovine serum albumin, and immunoglobulins.
- the group of ⁇ -lactoglobuiins accounts for about half of all whey proteins.
- the preferred whey protein is denatured and does not contain free a ino acids, caseins, casein-bound calcium and phosphate, fat and fat soluble vitamins.
- the w hey protein is denatured by the process of treating milk to make cheese as well as other pasteurization processes such as for example, low pH and high temperature pasteurization methods.
- the whey protein product is offered commercially under the name VersaPRO E from Davisco International, Inc., Le Sueur, Minnesota, or similar products may be obtained from other commercial sources.
- the other components of the present invention are known materials that are either commerciall available or readily prepared. These components are used in collagen enhancing effective amounts.
- collagen enhancing effective amount it is meant an amount which, in combination with the other essential components, enhances collagen production by at least 200 percent, preferably by at least 250 percent, most preferably by at least 300 percent.
- the collagen enhancing effective amount varies depending upon the identity of the components and their potency.
- the remaining components are essential to fortifying the effect of the compositions of the present invention as collagen synthesis enhancers.
- the first additional component is vitamin A and derivatives thereof.
- vitamin A or retinoid in the present context is meant vitamin A (retinol) and any natural or synthetic derivatives, homologs or analogs thereof suitable for use on the skin.
- retinoids in addition to retinol include, but are not limited to, retinoic acid (vitamin A acid), retinal (vitamin A aldehyde), and retinoic acid esters or amides, e.g., retinyl palmitate or retinyl acetate.
- vitamin E Another additional component is vitamin E or a homolog, analog or derivative thereof.
- the principle active component of v itamin E is tocopherol. particularly ⁇ -tocopherol: however. any vitamin E or tocopherol derivative may be employed.
- useful derivatives include but are not limited to, for example, esters such as tocopherol acetate, tocopherol linoleate, tocopherol nicotinate, tocopherol sorbate, or tocopherol succinate; polyethylene glycol ethers of tocopherol, such as tocophereth-5, tocophereth- 10, tocophereth- 12, tocophereth-18 or tocophereth-50 and 6-hydroxychroman homologs, particularly 6-hydroxy-2,5,7,8- tetramethylchroman-2-chroman-2-carboxylic acid, commercially available as Trolox®-C and troloxyl-amino acids.
- the tocopherol derivative may also be a tocopherol-cysteamine or cosmetically or pharmaceutically acceptable salts thereof.
- the tocopherol-cysteamine compounds can be made using readily available starting materials. It is within the scope of the present invention to use more than one vitamin E component in the mixture, for example, a mixture " containing both ⁇ -tocopherol and tocopherol cysteamine.
- the third essential additional component is vitamin C or a homolog, analog or derivative thereof.
- vitamin C which may be used include but are not limited to, for example, ascorbyl esters of fatty acids, such as ascorby palmitate. ascorbyl dipalmitate, ascorbyl dimethylsilanol palmitate, and ascorby stearate, ascorbyl linoleate, ascorbyl acetate; metal or metal phosphate salts, such as magnesium, sodium, or potassium ascorbyl phosphate, or magnesium, sodium or potassium ascorbate.
- the increase in collagen synthesis experienced with the present invention is especially surprising because a combination of about 1000 ⁇ g/ml of vitamin E, about 100 ⁇ g/ml of vitamin C, about 5 ⁇ g/ml of vitamin A and about 1 ,000 ⁇ g/ml of the whey protein (132% increase) is only merely as effective as about 100 ⁇ g/ml of vitamin C alone ( 128% increase) indicating that not all combinations of known collagen enhancers result in a significant additive increase in synthesis.
- the vitamin E component is present in an amount of less than about 800 ⁇ g/ml, more preferably less than about 500 ⁇ g/ml and the vitamin C component is present in an amount of from about 20 to about 200 ⁇ g/ml, more preferably from about 50 to about 100 ⁇ g/ml.
- the vitamin C component is present, however, in an amount less than the vitamin E component.
- the vitamin C component is present in an amount of about 20 ⁇ g/ml to about 80 ⁇ g/ml, most preferably 20 to 50 ⁇ g/ml and the vitamin E component is present in an amount of greater than about 500 ⁇ g/ml, preferably greater than about 800 ⁇ g/ml, and most preferably greater than 1000 ⁇ g/ml.
- the whey protein is present in the compositions of the invention in an amount of about 50 to about 10,000 ⁇ g/ml, preferably about 750 to about 5,000, and most preferably about 1,000 ⁇ g/ml.
- the vitamin A component is typically present in an amount of from about 1 to about 100 ⁇ g/ml, more preferably from about 2 to about 20 ⁇ g/ml, and most preferably from about 3.5 to about 5.0 ⁇ g/ml.
- the whey protein-containing compositions can be combined with a cosmetically and/or pharmaceutically acceptable carrier.
- pharmaceutically or cosmetically acceptable carrier refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms.
- pharmaceutical or cosmetic will be understood to encompass both human and annual pharmaceuticals or cosmetics.
- Useful carriers include, example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane- 1,3-diol, isoprop l myristate, isopropyl palmitate, or mineral oil.
- Methodology and components for formulation of cosmetic and pharmaceutical compositions are well known, and can be found, for example, in Remington's Pharmaceutical Sciences. Eighteenth Edition, A.R. Gennaro, Ed., Mack Publishing Co. Easton Pennsylvania, 1990.
- the carrier may be in any form appropriate for topical application to the skin, such forms include but are not limited to for example, solutions, colloidal dispersions, emulsions (oil-in- vvater or water-in-oil), suspensions, creams, lotions, gels, foams, mousses, sprays and the like.
- the collagen synthesis enhancing compositions can be prepared in any form convenient for topical application to the skin. As will be apparent, the composition can be a therapeutic product, the whey protein, vitamin A component, v itamin E component and vitamin C component being the sole actives.
- the compo jitions of the present invention may also comprise additional useful active ingredients which include, but are not limited to antioxidants, antimicrobials, analgesics, anesthetics, anti-acne agents, antidermatitis agents, antipru ⁇ tic agents, anti-inflammatory agents, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipso ⁇ atic agents, antiseborrheic agents, antiaging agents, antiwrinkle agents, skin lightening agents, depigmenting agents, wound-healing agents, corticosteroids, additional tanning agents, or hormones
- additional useful active ingredients include, but are not limited to antioxidants, antimicrobials, analgesics, anesthetics, anti-acne agents, antidermatitis agents, antipru ⁇ tic agents, anti-inflammatory agents, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipso ⁇ atic agents, antiseborrheic agents, antiaging agents, antiwrinkle agents
- the formulation in addition to the carrier and the essential component mixture, also can comprise other components which may be chosen depending on the carrier and/or the intended use of the-formulation Additional components include, but are not limited to, water soluble colorants (such as FD&C Blue # 1 ). oil soluble colorants (such as D&C Green #6), water soluble sunscreens (such as Eusolex 232), oil soluble sunscreens (such as octyl methoxycmnamate) paniculate sunscreens (such as zinc oxide), antioxidants (such as BHT), chelatirg agents (such as disodium EDTA). emulsion stabilizers (such as carbomer). preservatives (such as methy l paraben). fragrances (such as pinene).
- water soluble colorants such as FD&C Blue # 1
- oil soluble colorants such as D&C Green #6
- water soluble sunscreens such as Eusolex 232
- oil soluble sunscreens such as octyl methoxycmnam
- flavoring agents such as sorbitol
- humectants such as glycerine
- waterproofing agents such as PVP/eicosene copolymer
- water soluble film-formers such as hydroxypropy l methy lcellulose.
- oil-soluble film formers such as hydrogenated C-9 resin
- cationic polymers such as polyquatern ⁇ um- 10
- anionic polymers such as xanthan gum
- the present invention also in udes methods of enhancing the synthesis of collagen in skin m which an effectiv e amount of the hey protein-containing compositions is applied to the skin
- the compositions of the inv ention can be applied on an as-needed basis, for example, they can be applied to the skin before anticipated prolonged sun exposure, or during or after such exposure Howev er, a preferred method of obtaining the benefits of the composition is via chronic topical application of a safe and effective amount of a composition containing the mixture, to prevent the onset of undesirable effects of a reduction in collagen in the skin or the development of skin damage which may occur naturally or may result from exposure to UV light or other env ironmental insults which may in turn result in the degradation of collagen, or prevent worsening of or rev erse existing damage
- topical application be w ithin a range of from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily , most preferably about once or twice per day
- the composition combines one or more sunscreens with the active components
- the combination may be with any sunscreen
- sunscreens useful in the compositions include, but are not limited to, inorganic sunscreens such as titanium and zinc oxides, or organic sunscreens such as para-amino benzoic acid (PABA) and its esters, benzophenones, pheny l or homomenthyl salicylates, and cinnamates
- PABA para-amino benzoic acid
- the sunscreen of choice is employed in an amount consistent with the established use of that sunscreen
- the hey protein-containing compositions of the present invention can also be a makeup product, for example, a lipstick, foundation, concealer, bronzer, blush, eyeshadow and the like
- Various other optional ingredients may be included with the whey protein-containing compositions of the present invention, these include but are not limited to fragrants, perfumes, flavorings, preservatives emollients antiseptics, pigments, dyes, colorants, humectants, propellants waterproofing agents, film formers v itamins as well as other classes of materials whose presence may be cosmeticalh pharmaceutically, medicinally or otherwise desirable Common examples can be found in the CTFA International Cosmetic Ingredient Dictionary 4th Edition The Cosmetic Toiletry, and Fragrance Association, Inc , Washington, D C , 1991 , the contents of which are incorporated herein
- the hey protein is prepared by a series of steps First, whey is produced as a byproduct of the manufacturing of cheese and is isolated The whey supply is initially purified using a cla ⁇ fier which removes fine pieces or particles of cheese and casein An additional purification step involves ultrafiltration to separate the whey protein from lactose and other low molecular weight components in the w ev Next the whey protein is purified by diafiltration Purified water is used to wash out lactose and minerals Finally, the whey protein is dried at low temperatures with a high velocity spray dryer The resulting whey protein is a dry fine white powder
- Vitamins A, C, and E are added in amounts according to the present invention to the appropriate formulation chosen based on its desired use as a product to achieve the additional effect of enhanced collagen synthesis
- -It is surprising and unexpected to find that a combination of vitamin A, vitamin C and whey protein and the higher level of vitamin E results in a greater percent increase in production of collagen than vitamin E at the lower level because there is little effect on the level of collagen produced when the amount of vitamin C alone or in combination with the whey protein is doubled from 50 ⁇ g/ml to 100 ⁇ g/ml.
- the present invention is most surprising in light of the decrease in collagen synthesis when vitamin C is doubled from 50 ⁇ g/ml (336% synthesis) to 100 ⁇ g/ml in the presence of v itamin E at the high level of 1000 ⁇ g/ml ( 132% synthesis) and the other components.
- vitamin A the high and low levels are 5 ⁇ g'ml and w ithout: for v itamin C, the high and low levels are 100 and 50 ⁇ g/ml; and for vitamin E, the high and low levels are 1 ,000 and 500 ⁇ g/ml. Uniform conditions are maintained with respect to the whey protein which is in an amount of 1,000 ⁇ g/ml.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18171/00A AU742131B2 (en) | 1998-11-10 | 1999-11-10 | Topical compositions containing whey proteins |
JP2000580583A JP3803030B2 (en) | 1998-11-10 | 1999-11-10 | Topical composition containing whey protein |
EP99961639A EP1047398A1 (en) | 1998-11-10 | 1999-11-10 | Topical compositions containing whey proteins |
CA002317049A CA2317049A1 (en) | 1998-11-10 | 1999-11-10 | Topical compositions containing whey proteins |
KR10-2000-7007563A KR100499294B1 (en) | 1998-11-10 | 1999-11-10 | Topical Compositions Containing Whey Proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/189,829 US6203805B1 (en) | 1998-11-10 | 1998-11-10 | Topical compositions containing whey proteins |
US09/189,829 | 1998-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000027352A1 true WO2000027352A1 (en) | 2000-05-18 |
Family
ID=22698944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/026650 WO2000027352A1 (en) | 1998-11-10 | 1999-11-10 | Topical compositions containing whey proteins |
Country Status (8)
Country | Link |
---|---|
US (1) | US6203805B1 (en) |
EP (2) | EP1047398A1 (en) |
JP (1) | JP3803030B2 (en) |
KR (1) | KR100499294B1 (en) |
AU (1) | AU742131B2 (en) |
CA (1) | CA2317049A1 (en) |
WO (1) | WO2000027352A1 (en) |
ZA (1) | ZA200003283B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527540A (en) * | 2001-04-19 | 2004-09-09 | エゼンベルグ,ジョゼ | Cosmetic for preserving epidermis containing trimolecular complex as a main component |
FR2882928A1 (en) * | 2005-03-09 | 2006-09-15 | Jean Noel Thorel | Cosmetic composition, useful to regenerate, restructure and stimulate derma, comprises palmitoyl-3-pentapeptide in combination with Centella asiatica extract |
EP1708677A2 (en) * | 2004-01-07 | 2006-10-11 | E-L Management Corp. | Cosmetic composition containing a protein and an enzyme inhibitor |
WO2007110589A1 (en) * | 2006-03-24 | 2007-10-04 | Quest International Services B.V. | Use of fermented milk product for skin treatment |
EP3405172A4 (en) * | 2016-01-21 | 2019-09-18 | ELC Management LLC | Methods and compositions for treating aged skin |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6203805B1 (en) * | 1998-11-10 | 2001-03-20 | Color Access, Inc. | Topical compositions containing whey proteins |
ATE324800T1 (en) * | 2000-05-30 | 2006-06-15 | Nestle Sa | PRIMARY COMPOSITION CONTAINING A LIPOPHILIC BIOACTIVE SUBSTANCE |
US20050106219A1 (en) * | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
EP1297821A1 (en) * | 2001-10-01 | 2003-04-02 | Hive of Beauty (Europe) BVBA | Skin treatment compositions |
US6725486B2 (en) * | 2002-02-20 | 2004-04-27 | Oka Tool Company | Pipe fitting tool |
BR0309127A (en) * | 2002-04-09 | 2005-02-01 | Otsuka Pharma Co Ltd | Composition for cell proliferation |
US20050043217A1 (en) * | 2003-08-21 | 2005-02-24 | Christopher Marrs | Stabilized compositions containing an oxygen-labile active agent and lactoglobulin |
CA2541584C (en) * | 2003-10-08 | 2013-02-26 | Otsuka Pharmaceutical Co., Ltd. | Composition for promoting collagen production comprising a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance |
JP4596513B2 (en) * | 2003-10-14 | 2010-12-08 | 雪印乳業株式会社 | Nutritional composition |
US7160560B2 (en) * | 2003-10-23 | 2007-01-09 | L'oreal S.A. | Skin-care composition |
CN100548266C (en) * | 2004-01-24 | 2009-10-14 | 荷兰联合利华有限公司 | Skin whitening composition |
JP2006117552A (en) * | 2004-10-19 | 2006-05-11 | Hayashibara Biochem Lab Inc | Skin care preparation for photo-aging prevention |
JP4523388B2 (en) * | 2004-11-19 | 2010-08-11 | 日本メナード化粧品株式会社 | Collagen synthesis promoter and skin external preparation |
US7628907B2 (en) * | 2005-08-26 | 2009-12-08 | Honeywell International Inc. | Gas sensor |
US20080233075A1 (en) * | 2007-03-22 | 2008-09-25 | Marina Sokolinsky | Cosmetic composition for skin tightening |
EP2262469A4 (en) * | 2008-04-15 | 2013-12-04 | Immanence Integrale Dermo Correction Inc | Skin care compositions and methods of use thereof |
JP2011246442A (en) * | 2010-04-28 | 2011-12-08 | Rohto Pharmaceutical Co Ltd | Photoaging inhibitor and inhibitor to skin thinning |
DE102011106697A1 (en) * | 2011-03-09 | 2012-09-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Active substance-containing foam and method and composition for its production |
JP5980519B2 (en) * | 2012-02-15 | 2016-08-31 | 株式会社ディーエイチシー | AMPK activator |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
CA2883720A1 (en) | 2012-09-14 | 2014-03-20 | Klox Technologies Inc. | Cosmetic biophotonic compositions |
US9585943B2 (en) * | 2014-02-03 | 2017-03-07 | George D. Petito | Composition for tissue/cell repair |
JP7017311B2 (en) | 2014-06-09 | 2022-02-08 | 広東科洛克生物医薬集団有限公司 | Silicon-based bio-light composition and its use |
CA3009922A1 (en) | 2015-12-28 | 2017-07-06 | Klox Technologies Limited | Peroxide-less biophotonic compositions and methods |
CA3010886A1 (en) | 2016-01-11 | 2017-07-20 | Klox Technologies Limited | Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections |
US10149811B2 (en) * | 2016-02-11 | 2018-12-11 | Elc Management Llc | Methods and compositions for stimulating collagen synthesis in skin cells |
EP3463268B1 (en) | 2016-05-23 | 2021-11-03 | Klox Technologies Limited | Biophotonic compositions and uses thereof |
EP3558374A4 (en) | 2016-12-23 | 2020-08-12 | Klox Technologies Inc. | Biophotonic compositions comprising lichen extract and their use to treat skin disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58198409A (en) * | 1982-05-14 | 1983-11-18 | Yakult Honsha Co Ltd | Cosmetic |
US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4223018A (en) | 1979-02-09 | 1980-09-16 | Jimmie Belle | Bath composition |
CA1333471C (en) | 1988-04-29 | 1994-12-13 | Gustavo Bounous | Whey protein concentrate as food supplement |
US5456924A (en) | 1988-12-23 | 1995-10-10 | Immunotec Research Corporation Ltd. | Method of treatment of HIV-seropositive individuals with dietary whey proteins |
US5574063A (en) * | 1989-10-12 | 1996-11-12 | Perricone; Nicholas V. | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage |
US5386012A (en) | 1990-02-06 | 1995-01-31 | Strid; Lars | Growth factor in connection with artificial implants |
TW211523B (en) * | 1992-06-29 | 1993-08-21 | Amerchol Corp | Hydroxylated milk glycerides |
FR2717389B1 (en) | 1994-03-18 | 1996-06-07 | Lvmh Rech | Use of ginsenoside Ro or a plant extract containing it to stimulate the synthesis of collagen. |
CA2204777A1 (en) * | 1994-11-15 | 1996-05-23 | Steven Scott Porter | Skin care compositions and methods |
JP3542665B2 (en) | 1995-07-07 | 2004-07-14 | 株式会社資生堂 | Anti-aging skin external preparation, collagen cross-linking inhibition skin external preparation and anti-ultraviolet skin external preparation |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5667791A (en) * | 1996-05-31 | 1997-09-16 | Thione International, Inc. | X-ray induced skin damage protective composition |
US5690947A (en) * | 1996-08-30 | 1997-11-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids |
US6203805B1 (en) * | 1998-11-10 | 2001-03-20 | Color Access, Inc. | Topical compositions containing whey proteins |
-
1998
- 1998-11-10 US US09/189,829 patent/US6203805B1/en not_active Expired - Lifetime
-
1999
- 1999-11-10 KR KR10-2000-7007563A patent/KR100499294B1/en active IP Right Grant
- 1999-11-10 EP EP99961639A patent/EP1047398A1/en not_active Withdrawn
- 1999-11-10 JP JP2000580583A patent/JP3803030B2/en not_active Expired - Lifetime
- 1999-11-10 WO PCT/US1999/026650 patent/WO2000027352A1/en active IP Right Grant
- 1999-11-10 AU AU18171/00A patent/AU742131B2/en not_active Ceased
- 1999-11-10 CA CA002317049A patent/CA2317049A1/en not_active Abandoned
- 1999-11-10 EP EP01113964A patent/EP1129699A1/en not_active Withdrawn
-
2000
- 2000-06-29 ZA ZA200003283A patent/ZA200003283B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58198409A (en) * | 1982-05-14 | 1983-11-18 | Yakult Honsha Co Ltd | Cosmetic |
US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 008, no. 034 (C - 210) 15 February 1984 (1984-02-15) * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527540A (en) * | 2001-04-19 | 2004-09-09 | エゼンベルグ,ジョゼ | Cosmetic for preserving epidermis containing trimolecular complex as a main component |
EP1708677A2 (en) * | 2004-01-07 | 2006-10-11 | E-L Management Corp. | Cosmetic composition containing a protein and an enzyme inhibitor |
EP1708677A4 (en) * | 2004-01-07 | 2010-12-22 | E L Management Corp | Cosmetic composition containing a protein and an enzyme inhibitor |
FR2882928A1 (en) * | 2005-03-09 | 2006-09-15 | Jean Noel Thorel | Cosmetic composition, useful to regenerate, restructure and stimulate derma, comprises palmitoyl-3-pentapeptide in combination with Centella asiatica extract |
WO2007110589A1 (en) * | 2006-03-24 | 2007-10-04 | Quest International Services B.V. | Use of fermented milk product for skin treatment |
EP3405172A4 (en) * | 2016-01-21 | 2019-09-18 | ELC Management LLC | Methods and compositions for treating aged skin |
Also Published As
Publication number | Publication date |
---|---|
US6203805B1 (en) | 2001-03-20 |
EP1047398A1 (en) | 2000-11-02 |
JP3803030B2 (en) | 2006-08-02 |
EP1129699A1 (en) | 2001-09-05 |
AU742131B2 (en) | 2001-12-20 |
JP2002529387A (en) | 2002-09-10 |
CA2317049A1 (en) | 2000-05-18 |
ZA200003283B (en) | 2001-01-18 |
AU1817100A (en) | 2000-05-29 |
KR100499294B1 (en) | 2005-07-07 |
KR20010015900A (en) | 2001-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6203805B1 (en) | Topical compositions containing whey proteins | |
US5965145A (en) | Use of honey as keratolytic agent for improving the radiance and the complexion of the skin and treating wrinkles | |
US4537782A (en) | Emulsifying system based on a fatty acid or a protein condensate, a polyoxyethylenated sterol and a phosphatide, and a cosmetic or pharmaceutical composition containing the same | |
US5153230A (en) | Topical skin cream composition | |
US4474763A (en) | Skin preparation | |
JP4990268B2 (en) | Personal care compositions containing dipeptides | |
US4707354A (en) | Mature skin treatment and protectant compositions and methods of using same | |
US20030095933A1 (en) | Anti-aging skin care composition and uses thereof | |
HUT73064A (en) | Cosmetical and dermatological composition containing receptor agonist associated with chlorine-canal | |
CN111000748A (en) | Polypeptide repairing cream and preparation method thereof | |
WO2002011717A9 (en) | Cosmetics to support skin metabolism | |
JPH09183718A (en) | Composition suitable for external application | |
JPH08198741A (en) | Biological hyarulonic acid synthesis promoter | |
JPH0338511A (en) | External preparation | |
JP3643788B2 (en) | Topical skin preparation | |
AU2014271339B2 (en) | Personal care compositions | |
JP2001316238A (en) | Skin cosmetic | |
JPH0570333A (en) | Skin medicine for external use | |
JPH1025226A (en) | Hair growing and restoring agent | |
JP2000247825A (en) | Cosmetic and external preparation | |
JP2000072614A (en) | Skin cosmetic | |
EP0087374B1 (en) | Allantoin-hydrolyzed animal protein product | |
JPH09295930A (en) | Cosmetic | |
JP2001039815A (en) | Cosmetic and preparation for external use | |
JPH0570334A (en) | Skin medicine for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 18171 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18171/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2317049 Country of ref document: CA Ref country code: CA Ref document number: 2317049 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/03283 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007007563 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 580583 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999961639 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999961639 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007007563 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 18171/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999961639 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007007563 Country of ref document: KR |